content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-<U>_______</U></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM S-8</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REGISTRATION STATEMENT</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDER</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SECURITIES ACT OF 1933</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified
  in Its Charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%; padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
      or Other Jurisdiction of Incorporation or Organization)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">47-1685128</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
      Employer Identification No.)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="background-color: White; border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center">4400 Route 9 South, Suite 3100</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Freehold, New Jersey</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">07728</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 50%; text-align: center; padding-left: 1pt">(Address of Principal Executive Offices)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 49%; text-align: center; padding-left: 1pt">(Zip Code)</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.05pt 0pt 1pt; text-align: center">Avalon GloboCare Corp.</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.05pt 0pt 1pt; text-align: center">2020 Incentive Stock
          Plan</P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Full
      Title of the Plan)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luisa
      Ingargiola, Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4400
      Route 9 South, Suite 3100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Freehold,
      New Jersey 07728</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
      and Address of Agent For Service)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(732)
      780-4400</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 1.8pt; padding-left: 1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Telephone
      Number, Including Area Code, of Agent For Service)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
      <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
      <TD STYLE="width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
  by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to section 7(a)(2)(B) of the Securities Act: &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CALCULATION OF REGISTRATION FEE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Title of Securities to be Registered</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.05pt 0pt 1pt; text-align: center"><B>Amount</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.05pt 0pt 1pt; text-align: center"><B>To
                                           Be<BR>
   Registered (1)</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Offering
      Price Per Share (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum Aggregate
      Offering Price (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of Registration Fee
      (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: -0.125in; width: 47%; text-align: left; padding-left: 0.125in">Common Stock, $0.0001 par value per
      share, to be issued under the 2020 Incentive Stock Plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 15%; text-align: right; padding-left: 1pt">5,000,000 shares</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">670.97</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-left: 1pt">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: right; padding-left: 1pt">&nbsp;</TD><TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Common Stock, $0.0001 par
      value per share, to be issued under outstanding Stock Options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="text-align: right; padding-bottom: 1.5pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,096,667
      shares</FONT></TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 1.5pt">(3)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">1.23</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">8,728,900</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">952.23</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,623.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule
                                           416(a) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                           this Registration Statement shall also cover any additional shares of Common Stock attributable
                                           to these registered shares which become issuable under the Avalon GloboCare Corp. 2020
                                           Incentive Stock Plan by reason of any stock dividend, stock split, recapitalization or
                                           other similar transaction effected without the Registrant&rsquo;s receipt of consideration
                                           which results in an increase in the number of the outstanding shares of the Registrant&rsquo;s
                                           Common Stock.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h)
                                           under the Securities Act of 1933. The above calculation is based on the average of the
                                           high and low prices as reported by NASDAQ on December 2, 2020, which was $1.23 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Represents 7,096,667
                                           shares of common stock to be issued upon exercise of outstanding stock options issued
                                           to officers, directors and consultants.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPLANATORY NOTE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">This Registration
  Statement registers shares of common stock, par value $0.0001 per share, of Avalon GloboCare Corp. (the &ldquo;Company&rdquo;),
  consisting of (i) shares that may in the future be issued under the 2020 Incentive Stock Plan (the &ldquo;2020 Plan&rdquo;) and
  (ii) shares of common stock to be issued upon exercise of outstanding stock options issued to officers, directors and consultants
  of the Company named in this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">This registration
  statement contains two parts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The first part contains
  a &ldquo;reoffer&rdquo; prospectus prepared in accordance with Part I of Form S-3 (in accordance with Instruction C of the General
  Instructions to Form S-8). The reoffer prospectus permits reoffers and resales on a continuous or delayed basis of certain of
  those shares referred to above that constitute &ldquo;control securities&rdquo; or &ldquo;restricted securities,&rdquo; within
  the meaning of the Securities Act, by certain of the Company&rsquo;s stockholders consisting of current directors and officers
  previously issued to them pursuant to the 2020 Plan. In addition, certain information relating to future issuances under the 2020
  Plan is omitted from Part I, as further described below in the following paragraph and under the heading &ldquo;Item 1. Plan Information&rdquo;.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The second part
  contains information required to be set forth in the registration statement pursuant to Part II of Form S-8. Pursuant to the Note
  to Part I of Form S-8, the 2020 Plan information specified by Part I of Form S-8 is not required to be filed with the Securities
  and Exchange Commission.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The Company will
  provide without charge to any person, upon written or oral request of such person, a copy of each document incorporated by reference
  in Item 3 of Part II of this registration statement (which documents are also incorporated by reference in the reoffer prospectus
  as set forth in Form S-8), other than exhibits to such documents that are not specifically incorporated by reference, the other
  documents required to be delivered to eligible employees pursuant to Rule 428(b) under the Securities Act and additional information
  about the plans.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Reoffer Prospectus</U></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,096,667 Shares</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AVALON GLOBOCARE CORP.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Common Stock par value $0.0001</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">This reoffer prospectus
  relates to 7,096,667 shares of common stock (the &ldquo;Shares&rdquo;), $0.0001 par value, of the &ldquo;Company,&rdquo; that
  may be offered from time to time by certain Selling Stockholders named in this reoffer prospectus (the &ldquo;Selling Stockholders&rdquo;).
  The Selling Stockholders may acquire up to 7,096,667 shares of common stock to be issued upon exercise of outstanding stock options.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">The Selling Stockholders
  may sell the shares directly or may sell them through brokers or dealers. Except for limited funds to be received upon exercise
  of the Stock Options assuming a cash exercise, the Company will not receive any of the proceeds from sales made under this reoffer
  prospectus. The Company is paying the expenses incurred in registering these shares, but all selling and other expenses incurred
  by each of the Selling Stockholders will be borne by that Selling Stockholder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">Our common shares
  are traded on the Nasdaq Capital Market under the symbol &ldquo;AVCO.&rdquo; On December 2, 2020, our closing price on the Nasdaq
  Capital Market was $1.23 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INVESTING IN OUR COMMON STOCK INVOLVES
  RISKS. PLEASE SEE THE INFORMATION DESCRIBED UNDER &ldquo;RISK FACTORS&rdquo; ON PAGE 3.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE COMMISSION NOR ANY STATE SECURITIES
  COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION
  TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this reoffer prospectus is
  December 8, 2020.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 93%; padding-right: 0; padding-left: 0"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; width: 7%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">BUSINESS OVERVIEW</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">RISK FACTORS</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">4</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">DETERMINATION OF OFFERING PRICE</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">4</TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">SELLING STOCKHOLDERS</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">4</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">8</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXPERTS</FONT></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center"></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">8</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: center">9</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No dealer, salesperson
  or other person is authorized to give any information or to represent anything not contained in this reoffer prospectus. You must
  not rely on any unauthorized information or representations. This reoffer prospectus and any prospectus supplement do not constitute
  an offer to sell or a solicitation of any offer to buy any securities in any jurisdiction to any person to whom it is unlawful
  to make such offer or solicitation in such jurisdiction. The information contained in this reoffer prospectus is current only
  as of its date.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
  all references in this reoffer prospectus to &ldquo;Workhorse,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo;
  &ldquo;us,&rdquo; or similar terms refer to Avalon GloboCare Corp. and its subsidiaries.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>CAUTIONARY STATEMENT REGARDING FORWARD
  LOOKING STATEMENTS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reoffer prospectus
  contains or incorporates by reference &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation
  Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, that are based on management&rsquo;s beliefs and
  assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by
  the following words: &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
  &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
  &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing&rdquo; or the negative of these terms or
  other comparable terminology, although not all forward-looking statements contain these words.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements involve
  risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially
  different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable
  basis for each forward-looking statement contained in this reoffer prospectus, we caution you that these statements are based
  on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.
  Forward-looking statements contained in or incorporated by reference in this reoffer prospectus include, but are not limited to,
  statements about:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
  impact that the&nbsp;COVID-19&nbsp;pandemic and measures to prevent its spread may have on our business operations, access to
  capital, research and development activities</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
  ability to attract and retain management;</FONT></TD>
  </TR></TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
  ability to raise capital when needed and on acceptable terms and conditions;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  intensity of competition;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
  economic conditions;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
  in regulations;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">whether the market for healthcare services continues
  to grow, and, if it does, the pace at which it may grow;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to continue as a going concern;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain listing of our common stock
  on the Nasdaq Capital Market; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to compete against large competitors in
  a rapidly changing market.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any forward-looking
  statement made by us in this reoffer prospectus speaks only as of the date of this reoffer prospectus. Factors or events that
  could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We
  may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not
  place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of
  any future acquisitions, investments or other strategic transactions we may make. We undertake no obligation to publicly update
  or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may
  be required by any applicable securities laws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>BUSINESS OVERVIEW</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Company</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Impact of
  COVID-19 on our Operations, Financial Condition, Liquidity and Results of Operations</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic
  on our operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence,
  including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic,
  and any additional preventative and protective actions that governments, or us, may determine are needed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The occurrence of COVID-19 pandemic had
  negatively impact on our operations. Some tenants have delayed on rent payment. Our general development operations have continued
  during the COVID-19 pandemic and we have not had significant disruption. However, we are uncertain if the COVID-19 pandemic will
  impact future operations at our laboratory, or our ability to collaborate with other laboratories and universities. In addition,
  we are unsure if the COVID-19 pandemic will impact future clinical trials. Given the dynamic nature of these circumstances, the
  duration of business disruption and reduced traffic, the related financial effect cannot be reasonably estimated at this time
  but is expected to adversely impact the Company&rsquo;s business for the year of 2020.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We have limited cash available to fund
  planned operations. However, the COVID-19 pandemic has created significant economic uncertainty and volatility in the credit and
  capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of
  strategic partnership arrangements but the ultimate impact of the COVID-19 pandemic on our ability to raise additional capital
  is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including
  the duration of the COVID-19 outbreak and new information which may emerge concerning the severity of the COVID-19 pandemic. We
  may not be able to raise sufficient additional capital and may tailor our operations based on the amount of funding we are able
  to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. Further, there is no assurance
  that capital available to us in any future financing will be on acceptable terms.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We are&nbsp;a clinical-stage, vertically
  integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell
  therapy, exosome technology, as well as&nbsp;COVID-19&nbsp;related diagnostics and therapeutics. We also provide strategic advisory
  and outsourcing services to facilitate and enhance our clients&rsquo; growth and development, as well as competitiveness in healthcare
  and CellTech industry markets. Through our subsidiary structure with unique integration of verticals from innovative&nbsp;R&amp;D&nbsp;to
  automated bioproduction and accelerated clinical development, we are establishing a leading role in the fields of cellular immunotherapy
  (including CAR-T/NK), exosome technology (ACTEX&trade;), and regenerative therapeutics.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Avalon achieves and fosters seamless integration
  of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
  Avalon&rsquo;s upstream innovative research includes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-development
  of Avalon Clinical-grade Tissue-specific Exosome (&ldquo;ACTEX&trade;&rdquo;) with Weill Cornell Medicine.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
  therapeutic and diagnostic targets development utilizing QTY-code protein design technology with Massachusetts Institute of Technology
  (MIT) including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Co-development of next generation, transposon-based,
  multi-target CAR-T, CAR-NK and other immune effector cell therapeutic modalities with Arbele Corp</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Strategic partnership with the University of Natural
  Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by an intranasal
  or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Avalon&rsquo;s midstream bio-processing
  and bio-production facility is located in Nanjing, China with state-of-the-art, automated GMP and QC/QA infrastructure for standardized
  bio-manufacturing of clinical-grade cellular products involved in our clinical programs in immune effector cell therapy, regenerative
  therapeutics, as well as bio-banking.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Avalon&rsquo;s downstream medical team
  and facility consists of top-rated affiliated hospital network and experts specialized in hematology, oncology, cellular immunotherapy,
  hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Our major clinical programs include:&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVA-001:
  Avalon has initiated its first-in-human clinical trial of CD19 CAR-T candidate, AVA-001 in August 2019 at the Hebei Yanda Lu Daopei
  Hospital and Beijing Lu Daopei Hospital in China (the world&rsquo;s single largest CAR-T treatment network with over 600 patients
  being treated with CAR-T) for the indication of relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin Lymphoma.
  The AVA-001 candidate (co-developed with China Immunotech Co. Ltd) is characterized by the utilization of 4-1BB (CD137) co-stimulatory
  signaling pathway, conferring a strong anti-cancer activity during pre-clinical study. It also features a shorter bio-manufacturing
  time which leads to the advantage of prompt treatment to patients where timing is important related hematologic malignancies.
  Avalon has plans to recruit 20 patients (under registered clinical trial NCT03952923) for safety and efficacy studies.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVA-101:
  Avalon&rsquo;s transposon-based, multi-targeted CAR-T candidate, AVA-101 (co-developed with Arbele Corp.) will enter pre-clinical
  process development and validation phase. AVA-101 features non-viral, transposon-engineered CAR-T with multiple anti-cancer targets,
  as well as possessing molecular safety-switch mechanism to minimize the side effects, such as cytokine release syndrome and neurotoxicity,
  often associated with conventional CAR-T cellular therapy. Following the pre-clinical process development and validation phase,
  Avalon anticipates that it intends to pursue first-in-human clinical study of this next generation of potentially more effective
  and safer CAR-T candidate.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTEX&trade;:
  Stem cell-derived Avalon Clinical-grade Tissue-specific Exosomes (ACTEX&trade;) is one of the core technology platforms that has
  been co-developed by Avalon GloboCare and Weill Cornell Medicine. The Company formed a strategic partnership with HydroPeptide,
  LLC, a leading epigenetics skin care company, to engage in co-development and commercialization of a series of clinical-grade,
  exosome-based cosmeceutical and orthopedic products. As part of this agreement, the Company signed a three-way Material Transfer
  Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FLASH-CAR&trade;:
  The Company advanced its next generation immune cell therapy using FLASH-CAR&trade; technology co-developed with the Company&rsquo;s
  strategic partner Arbele Limited. The adaptable FLASH-CAR&trade; platform can be used to create personalized cell therapy from
  a patient&rsquo;s own cells, as well as off-the-shelf cell therapy from a universal donor.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVA-Trap&trade;:
  Avalon&rsquo;s AVA-Trap&trade; therapeutic program plans to enter animal model testing followed by expedited clinical studies
  with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving
  cytokine storms. The Company initiated a sponsored research and co-development project with Massachusetts Institute of Technology
  (MIT) led by Professor Shuguang Zhang as Principal Investigator in May 2019. Using the unique QTY code protein design platform,
  six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective
  cytokines.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We generated revenue by providing medical
  related consulting services in advanced areas of immunotherapy and second opinion/referral services through our wholly-owned subsidiary
  Avalon (Shanghai) Healthcare Technology Co., Ltd., or Avalon Shanghai. We also own and operate rental commercial real property
  in New Jersey, where we are headquartered. We discontinued sales of exosome isolation systems in China and the United States through
  our joint venture Genexosome Technologies, Inc. However, we are actively developing other unrelated proprietary exosome related
  products for sale or licensure.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The value of the Renminbi (&ldquo;RMB&rdquo;),
  the main currency used in China, fluctuates and is affected by, among other things, changes in China&rsquo;s political and economic
  conditions. The conversion of RMB into foreign currencies such as the U.S. dollar have generally been based on rates set by the
  People&rsquo;s Bank of China, which are set daily based on the previous day&rsquo;s interbank foreign exchange market rates and
  current exchange rates on the world financial markets.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>RISK FACTORS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Investing in our common stock involves
  a high degree of risk. You should consider carefully the risks and uncertainties and all other information contained in this reoffer
  prospectus, including the risks and uncertainties concerning our business and an investment in our common stock discussed in our
  Annual Report on Form 10-K for the year ended December 31, 2019, as well as those discussed in our filings with the Securities
  and Exchange Commission, together with the other information contained in and incorporated by reference into this reoffer prospectus,
  before deciding whether to invest in our common stock. Such risks and uncertainties are not the only ones we face. Additional
  risks and uncertainties that we are unaware of, or that we believe are not material, may also become important factors that adversely
  affect our business. If any of such risks actually occurs, our business, financial condition, results of operations, and future
  prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you
  could lose part or all of your investment.</P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Amidst the COVID-19 outbreak, some tenants
  have delayed on rent payment. Our general development operations have continued during the COVID-19 pandemic and we have not had
  significant disruption. Currently we are unable to accurately predict the future impact of COVID-19 due to the developing circumstances
  and uncertainty surrounding this current pandemic, including the ultimate geographic spread of COVID-19, the severity of the disease,
  the duration of the outbreak, and effectiveness of the actions that may be taken by governmental authorities. Our management has
  been closely monitoring the impact caused by COVID-19 and we will continue to operate our business as steadily and safely as we
  can.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_004"></A>USE OF PROCEEDS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Except for limited funds to be received
  upon exercise of the Stock Options assuming a cash exercise, we will not receive any proceeds from the sale of any of our common
  stock by the Selling Stockholders. We have agreed to pay all expenses relating to registering the common stock covered by this
  reoffer prospectus. The Selling Stockholders will pay any brokerage commissions and/or similar charges incurred in connection
  with the sale of the common stock covered hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_005"></A>DETERMINATION OF OFFERING PRICE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The Selling Stockholders may sell the
  common shares issued to them from time-to-time at prices and on terms then prevailing or at prices related to the then current
  market price, or in negotiated transactions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_006"></A>SELLING STOCKHOLDERS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reoffer prospectus
  relates to 7,096,667 shares of common stock (the &ldquo;Shares&rdquo;), $0.0001 par value, of the &ldquo;Company,&rdquo; that
  may be offered from time to time by certain Selling Stockholders named in this reoffer prospectus (the &ldquo;Selling Stockholders&rdquo;).
  Such Shares include 7,096,667 shares of common stock to be issued upon exercise of outstanding stock options which have been fully
  vested.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
  sets forth, as of December 2, 2020, the number of shares beneficially owned by each current Selling Stockholder. The number of
  shares in the column &ldquo;Shares Beneficially Owned Prior to the Offering&rdquo; represents the total number of shares that
  a Selling Stockholder currently owns or has the right to acquire within sixty (60) days of December 2, 2020. The number of shares
  in the column &ldquo;Shares Which May be Offered&rdquo; represents all of the shares that a Selling Stockholder may offer under
  this reoffer prospectus and includes shares issuable upon the exercise of options and are not included in the column &ldquo;Beneficially
  Owned Prior to the Offering.&rdquo; The table and footnotes assume that the Selling Stockholders will sell all of the shares listed
  in the column &ldquo;Shares Which May be Offered.&rdquo; However, because the Selling Stockholders may sell all or some of their
  shares under this reoffer prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual
  number of shares that will be sold by the Selling Stockholders or that will be held by the Selling Stockholders after completion
  of any sales. We do not know how long the Selling Stockholders will hold the shares before selling them. Beneficial ownership
  is determined in accordance with Rule 13d-3 promulgated by the Securities and Exchange Commission under the Securities Exchange
  Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Except as described below, none of the Selling Stockholders has held
  any position or office, or has otherwise had a material relationship, with us or any of our subsidiaries within the past three
  years other than as a result of the ownership of our common stock or other securities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information concerning
  the Selling Stockholders may change from time to time and changed information will be presented in a supplement to this reoffer
  prospectus if and when necessary and required. If, subsequent to the date of this reoffer prospectus, we grant additional awards
  to the Selling Stockholders or to other affiliates under the 2020 Plan, we intend to supplement this reoffer prospectus to reflect
  such additional awards and the names of such affiliates and the amounts of securities to be reoffered by them.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Selling Stockholder (1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position with the Company</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Beneficially Owned Prior to Offering (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Which May be Offered (3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Beneficially Owned after Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 45%; text-align: left">David Jin (4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 18%; text-align: left">CEO and Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">550,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">15,450,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">James Gajewski (5)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Consultant</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Luisa Ingargiola (6)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">CFO</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Meng Li (7)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">COO and Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,600,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Michael Hsu (8)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Consultant</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Steven A. Sanders (9)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Steven Sukel (10)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Former Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Tevi Troy (11)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Thomas N. Tauzin (12)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Consultant</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">489,733</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Uwe Sleytr (13)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Consultant</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Wenzhao Lu (14)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,045,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,545,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Wilbert J. Tauzin II (15)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">690,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">William B Stilley, III (16)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Yancen Lu (17)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Yue (Charles) Li (18)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The address for each of the Selling Stockholders is c/o
  Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Under Rule 13d-3 of the Exchange Act, beneficial ownership
  includes any shares as to which the Selling Stockholder has sole or shared voting power or investment power and also any shares,
  which the Selling Stockholder has the right to acquire within 60 days. &ldquo;Shares Beneficially Owned after Offering&rdquo;
  assumes the sale of all of the common stock offered by this Reoffer Prospectus and no other purchases or sales of our common stock
  by the Selling Stockholders.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes shares that are issuable upon exercise of stock
  options issued pursuant to the Plan, some of which are not, and will not become vested within 60 days from December 2, 2020 and
  are not included in the calculation of &ldquo;Shares Beneficially Owned Prior to this Offering.&rdquo;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 150,000 shares of
  common stock at an exercise price of $2.00 per share and (ii) a stock option to acquire 400,000 shares of common stock at an exercise
  price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.80 per share, (ii) a stock option to acquire 20,000 shares of common stock at an exercise
  price of $1.86 per share, and (iii) a stock option to acquire 6,667 shares of common stock at an exercise price of $1.76 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 2,000,000 shares
  of common stock at an exercise price of $0.50 per share and (ii) a stock option to acquire 400,000 shares of common stock at an
  exercise price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 150,000 shares of
  common stock at an exercise price of $2.00 per share and (ii) a stock option to acquire 300,000 shares of common stock at an exercise
  price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $1.46 per share and (ii) a stock option to acquire 6,667 shares of common stock at an exercise
  price of $1.12 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(9)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.80 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $1.49 per share and (ii) a stock option to acquire 30,000 shares of common stock at an exercise
  price of $2.50 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(11)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.30 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(12)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 100,000 shares of
  common stock at an exercise price of $1.00 per share, (ii) a stock option to acquire 200,000 shares of common stock at an exercise
  price of $2.52 per share, (iii) a stock option to acquire 100,000 shares of common stock at an exercise price of $1.84 per share
  and (iv) a stock option to acquire 50,000 shares of common stock at an exercise price of $1.12 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(13)</TD><TD STYLE="text-align: justify">Includes a stock option to acquire 13,333 shares of common
  stock at an exercise price of $1.57 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(14)</TD><TD STYLE="text-align: justify">Includes a stock option to acquire 1,500,000 shares of
  common stock at an exercise price of $2.00 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(15)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 290,000 shares of
  common stock at an exercise price of $1.00 per share, (ii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $2.50 per share, (iii) a stock option to acquire 40,000 shares of common stock at an exercise price of $2.75 per share,
  (iv) a stock option to acquire 40,000 shares of common stock at an exercise price of $1.93 per share, (v) a stock option to acquire
  160,000 shares of common stock at an exercise price of $2.52 per share, (vi) a stock option to acquire 80,000 shares of common
  stock at an exercise price of $1.84 per share, and (vii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $1.12 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(16)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.30 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(17)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $1.49 per share, (ii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $2.50 per share, (iii) a stock option to acquire 50,000 shares of common stock at an exercise price of $2.75 per share,
  (iv) a stock option to acquire 150,000 shares of common stock at an exercise price of $2.00 per share, and (v) a stock option
  to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(18)</TD><TD STYLE="text-align: justify">Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $4.76 per share and (ii) a stock option to acquire 80,000 shares of common stock at an exercise
  price of $1.52 per share.</TD>
  </TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>PLAN OF DISTRIBUTION</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of this
  reoffer prospectus is to allow the Selling Stockholders to offer for sale Shares acquired by the Selling Stockholders prior to
  the date of this reoffer prospectus and include 7,096,667 shares of common stock to be issued upon exercise of outstanding stock
  options.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decision to sell
  any shares is within the discretion of the holders thereof, subject generally to our policies affecting the timing and manner
  of sale of common stock by certain individuals and certain volume limitations set forth in Rule 144(e) of the Securities Act.
  There can be no assurance that any of the shares will be sold by the Selling Stockholders. These dispositions may be at fixed
  prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
  at the time of sale, or at negotiated prices.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders
  may use any one or more of the following methods when disposing of common stock or interests therein:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in
  which the broker-dealer solicits purchasers;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt
  to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale
  by the broker-dealer for its account;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules
  of the applicable exchange;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">settlement of short sales entered into after the effective
  date of the registration statement of which this prospectus is a part;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">in transactions through broker-dealers that agree
  with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">through the writing or settlement of options or other
  hedging transactions, whether through an options exchange or otherwise;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a combination of any of the foregoing methods of sale;
  or</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable
  law.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Selling Stockholder
  effects such transactions by selling shares of our common stock to or through underwriters, broker-dealers or agents, such underwriters,
  broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholder
  or commissions from purchasers of our common stock for whom they may act as agent or to whom they may sell as principal (which
  discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary
  in the types of transactions involved).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder
  and any broker-dealer participating in the distribution of our common stock may be deemed to be &ldquo;underwriters&rdquo; within
  the meaning of the Securities Act of 1933, as amended, and any commission paid, or any discounts or concessions allowed to, any
  such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act of 1933, as amended. At
  the time a particular offering of the securities is made, a prospectus supplement, if required, will be distributed which will
  set forth the aggregate amount of securities being offered and the terms of the offering, including the name or names of any broker-dealers
  or agents, any discounts, commissions and other terms constituting compensation from the Selling Stockholder and any discounts,
  commissions or concessions allowed, reallowed or paid to broker-dealers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder
  may choose not to sell any or may choose to sell less than all of our common stock registered pursuant to the registration statement,
  of which this reoffer prospectus forms a part.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay the expenses
  of the registration of our common stock sold by the Selling Stockholders, including, without limitation, Securities and Exchange
  Commission filings fees; provided, however, that the Selling Stockholder will pay all underwriting discounts and selling commissions,
  if any. As and when we are required to update this reoffer prospectus, we may incur additional expenses.</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once sold under the
  registration statement, of which this reoffer prospectus forms a part, our common stock will be freely tradable in the hands of
  persons other than our affiliates. We have notified the Selling Stockholders of the need to deliver a copy of this reoffer prospectus
  in connection with any sale of the shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply
  with certain state securities laws, if applicable, the shares may be sold in such jurisdictions only through registered or licensed
  brokers or dealers. In certain states, the shares may not be sold unless the shares have been registered or qualified for sale
  in such state or an exemption from regulation or qualification is available and is complied with. Sales of shares must also be
  made by the Selling Stockholders in compliance with all other applicable state securities laws and regulations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to any
  shares sold hereunder, Selling Stockholders may, at the same time, sell any shares of common stock owned by them in compliance
  with all of the requirements of Rule 144, regardless of whether such shares are covered by this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sales by Affiliates and Sales of Restricted
  Securities</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Selling Stockholders
  who are considered &ldquo;affiliates&rdquo; of the Company, as defined in Rule 405 under the Securities Act, or who are selling
  &ldquo;restricted securities&rdquo;, as defined in Rule 144(a)(3) under the Securities Act, may not sell an amount of shares pursuant
  to this reoffer prospectus which exceeds in any three month period the amount specified in Rule 144(e) under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A>LEGAL MATTERS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Fleming PLLC, has passed upon the validity
  of the shares of our common stock offered by the Selling Stockholders under this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>WHERE YOU CAN FIND MORE INFORMATION</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We are subject to the informational requirements
  of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current reports, proxy
  statements and other information with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;). Such reports, proxy
  statements and other information can be read and copied at the Commission&rsquo;s public reference facilities at 100 F Street,
  N.E., Washington, D.C. 20549, at prescribed rates. Please call the Commission at 1-800-732-0330 for further information on the
  operation of the public reference facilities. In addition, the Commission maintains a website that contains reports, proxy and
  information statements and other information regarding registrants that file electronically with the Commission. The address of
  the Commission&rsquo;s website is www.sec.gov.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We make available free of charge on or
  through our website at www.workhorse.com, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
  Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act
  of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it
  to the Commission. Information on our website is not incorporated by reference in this prospectus and is not a part of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We will provide without charge to each
  person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information that
  has been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings,
  unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to
  us at: 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728, Attention: Chief Financial Officer.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A>INCORPORATION OF CERTAIN INFORMATION BY
  REFERENCE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The Commission allows us to &ldquo;incorporate
  by reference&rdquo; the information we have filed with it, which means that we can disclose important information to you by referring
  you to those documents. The information we incorporate by reference is an important part of this reoffer prospectus, and later
  information that we file with the Commission will automatically update and supersede this information. We incorporate by reference
  the documents listed below and any future documents we file with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d)
  of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination of
  the offering (excluding, in either case, information that has been &ldquo;furnished&rdquo; but not &ldquo;filed&rdquo; for purposes
  of the Exchange Act).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual
                                           Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020008655/f10k2019_avalonglobocare.htm">Form 10-K</A> for the fiscal year ended December 31, 2019, filed with the Securities
                                           and Exchange Commission on April 6, 2020;</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quarterly
                                           Reports on Form 10-Q for the fiscal quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020012325/f10q0320_avalonglob.htm">March 31, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020020912/f10q0620_avalonglobocare.htm">June 30, 2020</A>, and
                                           <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020035963/f10q0920_avalonglobocarecorp.htm">September 30, 2020</A>, filed with the Securities and Exchange Commission on May 14, 2020,
                                           August 7, 2020, and November 9, 2020, respectively;</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
                                           Reports on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020002851/f8k020520_avalonglob.htm">February 7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020_avalonglobocare.htm">February 24, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020008531/ea120327-8k_avalonglobocare.htm">April 3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020020508/ea125077-8k_avalon.htm">August 6, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020022774/ea125733-8k_avalonglobocare.htm">August 19, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020032702/ea128751-8k_avalonglobo.htm">October 22, 2020</A>, respectively;</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                           description of our common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418011914/s113745_8a12b.htm">Form 8-A</A> filed
                                           on November 2, 2018 pursuant to Section 12(b) of the Exchange Act, including any amendment
                                           or report updating such description.</FONT></TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Reoffer Prospectus</U></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7,096,667 Shares</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock par value $0.0001</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 8, 2020</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART I</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 1.&nbsp;&nbsp;&nbsp;Plan Information.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The documents containing
  the information specified in Item 1 will be sent or given to participants in the Avalon GloboCare Corp. 2020 Incentive Stock Plan
  as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Such documents are
  not required to be and are not filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) either as part
  of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents
  incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute
  a prospectus that meets the requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 2.&nbsp;&nbsp;&nbsp;Registrant Information and Employee
  Plan Annual Information.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon written or oral
  request, any of the documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents are
  incorporated by reference in this Section 10(a) Prospectus), other documents required to be delivered to eligible employees, non-employee
  directors and consultants, pursuant to Rule 428(b) are available without charge by contacting:</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Luisa Ingargiola, Chief Financial Officer</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Avalon GloboCare Corp.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4400 Route 9 South, Suite 3100</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Freehold, New Jersey 07728</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">732-780-4400</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART II</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 3.&nbsp;&nbsp;&nbsp;Incorporation of Documents by Reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following documents which have been
  filed by Avalon GloboCare Corp., a Delaware corporation (the &ldquo;Registrant&rdquo;), with the Commission are incorporated into
  this Registration Statement by reference:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual
  Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020008655/f10k2019_avalonglobocare.htm">Form 10-K</A> for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission on April 6,
  2020;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quarterly
  Reports on Form 10-Q for the fiscal quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020012325/f10q0320_avalonglob.htm">March 31, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020020912/f10q0620_avalonglobocare.htm">June 30, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020035963/f10q0920_avalonglobocarecorp.htm">September 30, 2020</A>, filed with the Securities
  and Exchange Commission on May 14, 2020, August 7, 2020, and November 9, 2020, respectively;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
  Reports on Form 8-K, filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020002851/f8k020520_avalonglob.htm">February 7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020_avalonglobocare.htm">February 24, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020008531/ea120327-8k_avalonglobocare.htm">April 3, 2020</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020020508/ea125077-8k_avalon.htm">August 6, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020022774/ea125733-8k_avalonglobocare.htm">August 19, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020032702/ea128751-8k_avalonglobo.htm">October 22, 2020</A>, respectively;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
  description of our common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418011914/s113745_8a12b.htm">Form 8-A</A> filed on November 2, 2018 pursuant to Section
  12(b) of the Exchange Act, including any amendment or report updating such description.</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents subsequently
  filed by the Registrant with the Commission pursuant to Sections&nbsp;13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to
  the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities
  then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this
  Registration Statement from the date of filing of such documents.&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained
  herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed
  document that also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement.&nbsp;Any
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 4.&nbsp;&nbsp;&nbsp;Description of Securities.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 5.&nbsp;&nbsp;&nbsp;Interests of Named Experts and Counsel.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Not Applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 6.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">Section&nbsp;102(b)(7)
  of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;) allows a corporation to provide in its certificate of incorporation
  that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for
  breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged
  in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in
  violation of Delaware corporate law or obtained an improper personal benefit. The Registrant&rsquo;s amended and restated certificate
  of incorporation provides for this limitation of liability.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">Section&nbsp;145
  of the DGCL, provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to
  be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
  investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was
  an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director,
  officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo;
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such
  action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or
  not opposed to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable
  cause to believe that his or her conduct was unlawful. A Delaware corporation may indemnify any persons who were or are a party
  to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person
  is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including
  attorneys&rsquo; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action
  or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the
  corporation&rsquo;s best interests, provided further that no indemnification is permitted without judicial approval if the officer,
  director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits
  or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including
  attorneys&rsquo; fees) which such officer or director has actually and reasonably incurred.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">Section&nbsp;145
  further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer,
  employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or
  agent of another corporation or enterprise, against any liability asserted against such person and incurred by such person in
  any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power
  to indemnify such person under Section&nbsp;145. The Registrant&rsquo;s amended and restated bylaws provide that we must indemnify
  and advance expenses to its directors and officers to the full extent authorized by the DGCL.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">Further, the
  Registrant has or will enter into indemnification agreements with each of its directors and executive officers that may be broader
  than the specific indemnification provisions contained in its amended and restated bylaws or the DGCL. Such agreements may require
  the Registrant, among other things, to advance expenses and otherwise indemnify its executive officers and directors against certain
  liabilities that may arise by reason of their status or service as executive officers or directors, to the fullest extent permitted
  by law. The Registrant intends to enter into indemnification agreements with any new directors and executive officers in the future.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">The indemnification
  rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under
  any statute, any provision of the Registrant&rsquo;s amended and restated certificate of incorporation, the Registrant&rsquo;s
  amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing,
  the Registrant shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted
  by such director or officer, unless such proceeding (or part thereof) has been authorized by the board of directors pursuant to
  the applicable procedure outlined in the amended and restated bylaws.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">Section&nbsp;174
  of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends
  or an unlawful stock purchase or redemption, may be held jointly and severally liable for such actions. A director who was either
  absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such
  actions to be entered in the books containing the minutes of the meetings of the board of directors at the time such action occurred
  or immediately after such absent director receives notice of the unlawful acts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify; background-color: white">The Registrant
  expects to maintain standard policies of insurance that provide coverage (1)&nbsp;to its directors and officers against loss rising
  from claims made by reason of breach of duty or other wrongful act and (2)&nbsp;to the Registrant with respect to indemnification
  payments that it may make to such directors and officers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 7.&nbsp;&nbsp; Exemption from Registration Claimed.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
  applicable.</FONT></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 8.&nbsp;&nbsp;&nbsp;Exhibits.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-indent: 0; border-bottom: Black 1.5pt solid; width: 8%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
      Number</B></FONT></TD>
      <TD STYLE="padding-right: 0; padding-bottom: 1.5pt; width: 1%; padding-left: 0; text-indent: 0"><B>&nbsp;</B></TD>
      <TD STYLE="text-indent: 0; border-bottom: Black 1.5pt solid; width: 91%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea131169ex4-1_avalonglobo.htm" STYLE="-sec-extract: exhibit">Avalon GloboCare Corp. 2020 Incentive Stock Plan</A> </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex5-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Fleming PLLC</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex23-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><A HREF="ea131169ex23-2_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of RBSM LLP</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex5-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Fleming PLLC (see Exhibit 5.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa">Power of Attorney (included in signature page)</A></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">Item 9.</TD><TD STYLE="text-align: justify">Undertakings.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  undersigned Registrant hereby undertakes:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR>
      <TD STYLE="vertical-align: bottom; width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 0.5in; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
      include any prospectus required by section 10(a)(3) of the Securities Act;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
      reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
      recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
      set forth in the registration statement.&nbsp;Notwithstanding the foregoing, any increase or decrease in volume of securities
      offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from
      the low or high and of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
      pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change
      in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective
      registration statement; and</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Page; Sequence: 20; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin: 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR>
      <TD STYLE="vertical-align: bottom; text-align: justify; width: 0.5in">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
      include any material information with respect to the plan of distribution not previously disclosed in the registration statement
      or any material change to such information in the registration statement;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided, however, that paragraphs (1)(a)(i)
  and (1)(a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange
  Act that are incorporated by reference in this registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR>
      <TD STYLE="vertical-align: bottom; width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 0.5in; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
      for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
      to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
      time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR>
      <TD STYLE="vertical-align: bottom; width: 0.5in; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 0.5in; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
      remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
      at the termination of the offering.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
  of the Registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by
  reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered
  therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
  of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the
  Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.&nbsp;In
  the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
  or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding)
  is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant
  will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
  by the final adjudication of such issue.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 21; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="poa"></A>SIGNATURES</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto
  duly authorized, in the City of Freehold, State of New Jersey on this 8th day of&nbsp;December 2020.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVALON
      GLOBOCARE CORP.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-right: 0; width: 60%; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; width: 4%; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; width: 36%; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      David K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; border-top: black 2.25pt solid; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
      K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
      Executive Officer and President</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
      Executive Officer)</I></FONT></TD></TR>
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: bottom; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="text-indent: 0; vertical-align: bottom; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Luisa Ingargiola</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; border-top: black 2.25pt solid; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luisa
      Ingargiola</FONT></TD></TR>
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
      Financial Officer</FONT></TD></TR>
  <TR>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
      Financial and Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each person whose
  signature appears below constitutes and appoints David K. Jin and Luisa Ingargiola, his true and lawful attorney-in-fact and agent,
  with full power of substitution and resubstitution, severally, for him and in his name, place and stead, in any and all capacities,
  in connection with the Registrant&rsquo;s Registration Statement on Form&nbsp;S-8 under the Securities Act of 1933, including
  to sign any and all amendments (including post-effective amendments or supplements) to this Registration Statement, and to file
  the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and
  any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, each acting
  alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
  the premises, as fully, to all intents and purposes, as he might or could do in person, hereby ratifying and confirming all that
  said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
  dates indicated.</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 33%; padding-right: 1.75pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%"><B>&nbsp;</B></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 38%; padding-right: 1.8pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TITLE</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%"><B>&nbsp;</B></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 25%; padding-right: 1.8pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      David K. Jin</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
      Executive Officer, President and Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
      K. Jin</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
      Executive Officer)</I></FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Luisa Ingargolia</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
      Financial Officer</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
      Schrader</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Principal
      Financial and Accounting Officer</I>)</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Wenzhao Lu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
      of the Board of Directors</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wenzhao
      Lu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Meng Li</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
      Operating Officer</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meng
      Li</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Steven A. Sanders</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
      A. Sanders</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Yancen Lu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yancen
      Lu</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Wilbert J. Tauzin II</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilbert
      J. Tauzin II</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      William B. Stilley III</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
      B. Stilley III</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Tevi Troy</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevi
      Troy</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Yue &ldquo;Charles&rdquo; Li</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 1.8pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
      8, 2020</FONT></TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; padding-right: 1.75pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yue
      &ldquo;Charles&rdquo; Li</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 22; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit Index</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-indent: 0; border-bottom: Black 1.5pt solid; width: 8%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
      Number</B></FONT></TD>
      <TD STYLE="padding-right: 0; padding-bottom: 1.5pt; width: 1%; padding-left: 0; text-indent: 0"><B>&nbsp;</B></TD>
      <TD STYLE="text-indent: 0; border-bottom: Black 1.5pt solid; width: 91%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; vertical-align: top; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex4-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avalon GloboCare Corp. 2020 Incentive Stock Plan </FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex5-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Fleming PLLC</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex23-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea131169ex23-2_avalonglobo.htm">Consent of RBSM LLP</A></FONT></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><A HREF="ea131169ex5-1_avalonglobo.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Fleming PLLC (see Exhibit 5.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="padding-right: 0; vertical-align: bottom; padding-left: 0; text-indent: 0">&nbsp;</TD>
      <TD STYLE="text-indent: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#poa">Power of Attorney (included in signature page)</A></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-6</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea131169-s8_avalonglobocare.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 189885}]
metadata_filer: {"company-data": {"conformed-name": "Avalon GloboCare Corp.", "cik": "0001630212", "assigned-sic": "8742", "irs-number": "471685128", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-251196", "film-number": "201375701"}, "business-address": {"street1": "4400 ROUTE 9", "street2": "SUITE 3100", "city": "FREEHOLD", "state": "NJ", "zip": "07728", "phone": "(646) 762-4517"}, "mail-address": {"street1": "4400 ROUTE 9", "street2": "SUITE 3100", "city": "FREEHOLD", "state": "NJ", "zip": "07728"}, "former-company": [{"former-conformed-name": "Avalon Globocare Corp.", "date-changed": "20161018"}, {"former-conformed-name": "GLOBAL TECHNOLOGIES CORP", "date-changed": "20150108"}]}
text: Registration No. 333-
  _______
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  AVALON GLOBOCARE CORP.
  (Exact Name of Registrant as Specified
  in Its Charter)
  Delaware
  (State
      or Other Jurisdiction of Incorporation or Organization)
  47-1685128
  (I.R.S.
      Employer Identification No.)
  4400 Route 9 South, Suite 3100
  Freehold, New Jersey
  07728
  (Address of Principal Executive Offices)
  (Zip Code)
  Avalon GloboCare Corp.
  2020 Incentive Stock
          Plan
  (Full
      Title of the Plan)
  Luisa
      Ingargiola, Chief Financial Officer
  4400
      Route 9 South, Suite 3100
  Freehold,
      New Jersey 07728
  (Name
      and Address of Agent For Service)
  (732)
      780-4400
  (Telephone
      Number, Including Area Code, of Agent For Service)
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☒
  If an emerging growth company, indicate
  by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to section 7(a)(2)(B) of the Securities Act: ☐
  CALCULATION OF REGISTRATION FEE
  Title of Securities to be Registered
  Amount
  To
                                           Be
  Registered (1)
  Proposed Maximum Offering
      Price Per Share (2)
  Proposed Maximum Aggregate
      Offering Price (2)
  Amount of Registration Fee
      (2)
  Common Stock, $0.0001 par value per
      share, to be issued under the 2020 Incentive Stock Plan
  5,000,000 shares
  $
  1.23
  $
  6,150,000
  $
  670.97
  Common Stock, $0.0001 par
      value per share, to be issued under outstanding Stock Options
  7,096,667
      shares
  (3)
  $
  1.23
  $
  8,728,900
  $
  952.23
  TOTAL
  $
  1,623.20
  (1)
  Pursuant to Rule
                                           416(a) of the Securities Act of 1933, as amended (the "Securities Act"),
                                           this Registration Statement shall also cover any additional shares of Common Stock attributable
                                           to these registered shares which become issuable under the Avalon GloboCare Corp. 2020
                                           Incentive Stock Plan by reason of any stock dividend, stock split, recapitalization or
                                           other similar transaction effected without the Registrant's receipt of consideration
                                           which results in an increase in the number of the outstanding shares of the Registrant's
                                           Common Stock.
  (2)
  Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h)
                                           under the Securities Act of 1933. The above calculation is based on the average of the
                                           high and low prices as reported by NASDAQ on December 2, 2020, which was $1.23 per share.
  (3)
  Represents 7,096,667
                                           shares of common stock to be issued upon exercise of outstanding stock options issued
                                           to officers, directors and consultants.
  EXPLANATORY NOTE
  This Registration
  Statement registers shares of common stock, par value $0.0001 per share, of Avalon GloboCare Corp. (the "Company"),
  consisting of (i) shares that may in the future be issued under the 2020 Incentive Stock Plan (the "2020 Plan") and
  (ii) shares of common stock to be issued upon exercise of outstanding stock options issued to officers, directors and consultants
  of the Company named in this Registration Statement.
  This registration
  statement contains two parts.
  The first part contains
  a "reoffer" prospectus prepared in accordance with Part I of Form S-3 (in accordance with Instruction C of the General
  Instructions to Form S-8). The reoffer prospectus permits reoffers and resales on a continuous or delayed basis of certain of
  those shares referred to above that constitute "control securities" or "restricted securities," within
  the meaning of the Securities Act, by certain of the Company's stockholders consisting of current directors and officers
  previously issued to them pursuant to the 2020 Plan. In addition, certain information relating to future issuances under the 2020
  Plan is omitted from Part I, as further described below in the following paragraph and under the heading "Item 1. Plan Information".
  The second part
  contains information required to be set forth in the registration statement pursuant to Part II of Form S-8. Pursuant to the Note
  to Part I of Form S-8, the 2020 Plan information specified by Part I of Form S-8 is not required to be filed with the Securities
  and Exchange Commission.
  The Company will
  provide without charge to any person, upon written or oral request of such person, a copy of each document incorporated by reference
  in Item 3 of Part II of this registration statement (which documents are also incorporated by reference in the reoffer prospectus
  as set forth in Form S-8), other than exhibits to such documents that are not specifically incorporated by reference, the other
  documents required to be delivered to eligible employees pursuant to Rule 428(b) under the Securities Act and additional information
  about the plans.
  Reoffer Prospectus
  7,096,667 Shares
  AVALON GLOBOCARE CORP.
  Common Stock par value $0.0001
  This reoffer prospectus
  relates to 7,096,667 shares of common stock (the "Shares"), $0.0001 par value, of the "Company," that
  may be offered from time to time by certain Selling Stockholders named in this reoffer prospectus (the "Selling Stockholders").
  The Selling Stockholders may acquire up to 7,096,667 shares of common stock to be issued upon exercise of outstanding stock options.
  The Selling Stockholders
  may sell the shares directly or may sell them through brokers or dealers. Except for limited funds to be received upon exercise
  of the Stock Options assuming a cash exercise, the Company will not receive any of the proceeds from sales made under this reoffer
  prospectus. The Company is paying the expenses incurred in registering these shares, but all selling and other expenses incurred
  by each of the Selling Stockholders will be borne by that Selling Stockholder.
  Our common shares
  are traded on the Nasdaq Capital Market under the symbol "AVCO." On December 2, 2020, our closing price on the Nasdaq
  Capital Market was $1.23 per share.
  INVESTING IN OUR COMMON STOCK INVOLVES
  RISKS. PLEASE SEE THE INFORMATION DESCRIBED UNDER "RISK FACTORS" ON PAGE 3.
  NEITHER THE COMMISSION NOR ANY STATE SECURITIES
  COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION
  TO THE CONTRARY IS A CRIMINAL OFFENSE.
  The date of this reoffer prospectus is
  December 8, 2020.
  TABLE OF CONTENTS
  CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
  ii
  BUSINESS OVERVIEW
  1
  RISK FACTORS
  3
  USE OF PROCEEDS
  4
  DETERMINATION OF OFFERING PRICE
  4
  SELLING STOCKHOLDERS
  4
  PLAN OF DISTRIBUTION
  7
  LEGAL MATTERS
  8
  EXPERTS
  WHERE YOU CAN FIND MORE INFORMATION
  8
  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
  9
  No dealer, salesperson
  or other person is authorized to give any information or to represent anything not contained in this reoffer prospectus. You must
  not rely on any unauthorized information or representations. This reoffer prospectus and any prospectus supplement do not constitute
  an offer to sell or a solicitation of any offer to buy any securities in any jurisdiction to any person to whom it is unlawful
  to make such offer or solicitation in such jurisdiction. The information contained in this reoffer prospectus is current only
  as of its date.
  Unless otherwise indicated,
  all references in this reoffer prospectus to "Workhorse," the "Company," "we," "our,"
  "us," or similar terms refer to Avalon GloboCare Corp. and its subsidiaries.
  i
  CAUTIONARY STATEMENT REGARDING FORWARD
  LOOKING STATEMENTS
  This reoffer prospectus
  contains or incorporates by reference "forward-looking statements" within the meaning of the Private Securities Litigation
  Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, that are based on management's beliefs and
  assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by
  the following words: "may," "will," "could," "would," "should," "expect,"
  "intend," "plan," "anticipate," "believe," "estimate," "predict,"
  "project," "potential," "continue," "ongoing" or the negative of these terms or
  other comparable terminology, although not all forward-looking statements contain these words.
  These statements involve
  risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially
  different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable
  basis for each forward-looking statement contained in this reoffer prospectus, we caution you that these statements are based
  on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.
  Forward-looking statements contained in or incorporated by reference in this reoffer prospectus include, but are not limited to,
  statements about:
  ●
  the
  impact that the COVID-19 pandemic and measures to prevent its spread may have on our business operations, access to
  capital, research and development activities
  ●
  our
  ability to attract and retain management;
  ●
  our
  ability to raise capital when needed and on acceptable terms and conditions;
  ●
  the
  intensity of competition;
  ●
  general
  economic conditions;
  ●
  changes
  in regulations;
  ●
  whether the market for healthcare services continues
  to grow, and, if it does, the pace at which it may grow;
  ●
  our ability to continue as a going concern;
  ●
  our ability to maintain listing of our common stock
  on the Nasdaq Capital Market; and
  ●
  our ability to compete against large competitors in
  a rapidly changing market.
  Any forward-looking
  statement made by us in this reoffer prospectus speaks only as of the date of this reoffer prospectus. Factors or events that
  could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We
  may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not
  place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of
  any future acquisitions, investments or other strategic transactions we may make. We undertake no obligation to publicly update
  or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may
  be required by any applicable securities laws.
  ii
  BUSINESS OVERVIEW
  Our Company
  Impact of
  COVID-19 on our Operations, Financial Condition, Liquidity and Results of Operations
  The ultimate impact of the COVID-19 pandemic
  on our operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence,
  including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic,
  and any additional preventative and protective actions that governments, or us, may determine are needed.
  The occurrence of COVID-19 pandemic had
  negatively impact on our operations. Some tenants have delayed on rent payment. Our general development operations have continued
  during the COVID-19 pandemic and we have not had significant disruption. However, we are uncertain if the COVID-19 pandemic will
  impact future operations at our laboratory, or our ability to collaborate with other laboratories and universities. In addition,
  we are unsure if the COVID-19 pandemic will impact future clinical trials. Given the dynamic nature of these circumstances, the
  duration of business disruption and reduced traffic, the related financial effect cannot be reasonably estimated at this time
  but is expected to adversely impact the Company's business for the year of 2020.
  We have limited cash available to fund
  planned operations. However, the COVID-19 pandemic has created significant economic uncertainty and volatility in the credit and
  capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of
  strategic partnership arrangements but the ultimate impact of the COVID-19 pandemic on our ability to raise additional capital
  is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including
  the duration of the COVID-19 outbreak and new information which may emerge concerning the severity of the COVID-19 pandemic. We
  may not be able to raise sufficient additional capital and may tailor our operations based on the amount of funding we are able
  to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. Further, there is no assurance
  that capital available to us in any future financing will be on acceptable terms.
  Overview
  We are a clinical-stage, vertically
  integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell
  therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. We also provide strategic advisory
  and outsourcing services to facilitate and enhance our clients' growth and development, as well as competitiveness in healthcare
  and CellTech industry markets. Through our subsidiary structure with unique integration of verticals from innovative R&D to
  automated bioproduction and accelerated clinical development, we are establishing a leading role in the fields of cellular immunotherapy
  (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
  Avalon achieves and fosters seamless integration
  of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
  Avalon's upstream innovative research includes:
  ●
  Co-development
  of Avalon Clinical-grade Tissue-specific Exosome ("ACTEX™") with Weill Cornell Medicine.
  ●
  Novel
  therapeutic and diagnostic targets development utilizing QTY-code protein design technology with Massachusetts Institute of Technology
  (MIT) including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm.
  ●
  Co-development of next generation, transposon-based,
  multi-target CAR-T, CAR-NK and other immune effector cell therapeutic modalities with Arbele Corp
  ●
  Strategic partnership with the University of Natural
  Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by an intranasal
  or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease.
  Avalon's midstream bio-processing
  and bio-production facility is located in Nanjing, China with state-of-the-art, automated GMP and QC/QA infrastructure for standardized
  bio-manufacturing of clinical-grade cellular products involved in our clinical programs in immune effector cell therapy, regenerative
  therapeutics, as well as bio-banking.
  1
  Avalon's downstream medical team
  and facility consists of top-rated affiliated hospital network and experts specialized in hematology, oncology, cellular immunotherapy,
  hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Our major clinical programs include:
  ●
  AVA-001:
  Avalon has initiated its first-in-human clinical trial of CD19 CAR-T candidate, AVA-001 in August 2019 at the Hebei Yanda Lu Daopei
  Hospital and Beijing Lu Daopei Hospital in China (the world's single largest CAR-T treatment network with over 600 patients
  being treated with CAR-T) for the indication of relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin Lymphoma.
  The AVA-001 candidate (co-developed with China Immunotech Co. Ltd) is characterized by the utilization of 4-1BB (CD137) co-stimulatory
  signaling pathway, conferring a strong anti-cancer activity during pre-clinical study. It also features a shorter bio-manufacturing
  time which leads to the advantage of prompt treatment to patients where timing is important related hematologic malignancies.
  Avalon has plans to recruit 20 patients (under registered clinical trial NCT03952923) for safety and efficacy studies.
  ●
  AVA-101:
  Avalon's transposon-based, multi-targeted CAR-T candidate, AVA-101 (co-developed with Arbele Corp.) will enter pre-clinical
  process development and validation phase. AVA-101 features non-viral, transposon-engineered CAR-T with multiple anti-cancer targets,
  as well as possessing molecular safety-switch mechanism to minimize the side effects, such as cytokine release syndrome and neurotoxicity,
  often associated with conventional CAR-T cellular therapy. Following the pre-clinical process development and validation phase,
  Avalon anticipates that it intends to pursue first-in-human clinical study of this next generation of potentially more effective
  and safer CAR-T candidate.
  ●
  ACTEX™:
  Stem cell-derived Avalon Clinical-grade Tissue-specific Exosomes (ACTEX™) is one of the core technology platforms that has
  been co-developed by Avalon GloboCare and Weill Cornell Medicine. The Company formed a strategic partnership with HydroPeptide,
  LLC, a leading epigenetics skin care company, to engage in co-development and commercialization of a series of clinical-grade,
  exosome-based cosmeceutical and orthopedic products. As part of this agreement, the Company signed a three-way Material Transfer
  Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine.
  ●
  FLASH-CAR™:
  The Company advanced its next generation immune cell therapy using FLASH-CAR™ technology co-developed with the Company's
  strategic partner Arbele Limited. The adaptable FLASH-CAR™ platform can be used to create personalized cell therapy from
  a patient's own cells, as well as off-the-shelf cell therapy from a universal donor.
  ●
  AVA-Trap™:
  Avalon's AVA-Trap™ therapeutic program plans to enter animal model testing followed by expedited clinical studies
  with the goal of providing an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving
  cytokine storms. The Company initiated a sponsored research and co-development project with Massachusetts Institute of Technology
  (MIT) led by Professor Shuguang Zhang as Principal Investigator in May 2019. Using the unique QTY code protein design platform,
  six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective
  cytokines.
  We generated revenue by providing medical
  related consulting services in advanced areas of immunotherapy and second opinion/referral services through our wholly-owned subsidiary
  Avalon (Shanghai) Healthcare Technology Co., Ltd., or Avalon Shanghai. We also own and operate rental commercial real property
  in New Jersey, where we are headquartered. We discontinued sales of exosome isolation systems in China and the United States through
  our joint venture Genexosome Technologies, Inc. However, we are actively developing other unrelated proprietary exosome related
  products for sale or licensure.
  The value of the Renminbi ("RMB"),
  the main currency used in China, fluctuates and is affected by, among other things, changes in China's political and economic
  conditions. The conversion of RMB into foreign currencies such as the U.S. dollar have generally been based on rates set by the
  People's Bank of China, which are set daily based on the previous day's interbank foreign exchange market rates and
  current exchange rates on the world financial markets.
  2
  RISK FACTORS
  Investing in our common stock involves
  a high degree of risk. You should consider carefully the risks and uncertainties and all other information contained in this reoffer
  prospectus, including the risks and uncertainties concerning our business and an investment in our common stock discussed in our
  Annual Report on Form 10-K for the year ended December 31, 2019, as well as those discussed in our filings with the Securities
  and Exchange Commission, together with the other information contained in and incorporated by reference into this reoffer prospectus,
  before deciding whether to invest in our common stock. Such risks and uncertainties are not the only ones we face. Additional
  risks and uncertainties that we are unaware of, or that we believe are not material, may also become important factors that adversely
  affect our business. If any of such risks actually occurs, our business, financial condition, results of operations, and future
  prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you
  could lose part or all of your investment.
  Amidst the COVID-19 outbreak, some tenants
  have delayed on rent payment. Our general development operations have continued during the COVID-19 pandemic and we have not had
  significant disruption. Currently we are unable to accurately predict the future impact of COVID-19 due to the developing circumstances
  and uncertainty surrounding this current pandemic, including the ultimate geographic spread of COVID-19, the severity of the disease,
  the duration of the outbreak, and effectiveness of the actions that may be taken by governmental authorities. Our management has
  been closely monitoring the impact caused by COVID-19 and we will continue to operate our business as steadily and safely as we
  can.
  3
  USE OF PROCEEDS
  Except for limited funds to be received
  upon exercise of the Stock Options assuming a cash exercise, we will not receive any proceeds from the sale of any of our common
  stock by the Selling Stockholders. We have agreed to pay all expenses relating to registering the common stock covered by this
  reoffer prospectus. The Selling Stockholders will pay any brokerage commissions and/or similar charges incurred in connection
  with the sale of the common stock covered hereby.
  DETERMINATION OF OFFERING PRICE
  The Selling Stockholders may sell the
  common shares issued to them from time-to-time at prices and on terms then prevailing or at prices related to the then current
  market price, or in negotiated transactions.
  SELLING STOCKHOLDERS
  This reoffer prospectus
  relates to 7,096,667 shares of common stock (the "Shares"), $0.0001 par value, of the "Company," that
  may be offered from time to time by certain Selling Stockholders named in this reoffer prospectus (the "Selling Stockholders").
  Such Shares include 7,096,667 shares of common stock to be issued upon exercise of outstanding stock options which have been fully
  vested.
  The following table
  sets forth, as of December 2, 2020, the number of shares beneficially owned by each current Selling Stockholder. The number of
  shares in the column "Shares Beneficially Owned Prior to the Offering" represents the total number of shares that
  a Selling Stockholder currently owns or has the right to acquire within sixty (60) days of December 2, 2020. The number of shares
  in the column "Shares Which May be Offered" represents all of the shares that a Selling Stockholder may offer under
  this reoffer prospectus and includes shares issuable upon the exercise of options and are not included in the column "Beneficially
  Owned Prior to the Offering." The table and footnotes assume that the Selling Stockholders will sell all of the shares listed
  in the column "Shares Which May be Offered." However, because the Selling Stockholders may sell all or some of their
  shares under this reoffer prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual
  number of shares that will be sold by the Selling Stockholders or that will be held by the Selling Stockholders after completion
  of any sales. We do not know how long the Selling Stockholders will hold the shares before selling them. Beneficial ownership
  is determined in accordance with Rule 13d-3 promulgated by the Securities and Exchange Commission under the Securities Exchange
  Act of 1934, as amended (the "Exchange Act"). Except as described below, none of the Selling Stockholders has held
  any position or office, or has otherwise had a material relationship, with us or any of our subsidiaries within the past three
  years other than as a result of the ownership of our common stock or other securities.
  4
  Information concerning
  the Selling Stockholders may change from time to time and changed information will be presented in a supplement to this reoffer
  prospectus if and when necessary and required. If, subsequent to the date of this reoffer prospectus, we grant additional awards
  to the Selling Stockholders or to other affiliates under the 2020 Plan, we intend to supplement this reoffer prospectus to reflect
  such additional awards and the names of such affiliates and the amounts of securities to be reoffered by them.
  Selling Stockholder (1)
  Position with the Company
  Shares Beneficially Owned Prior to Offering (2)
  Shares Which May be Offered (3)
  Shares Beneficially Owned after Offering
  David Jin (4)
  CEO and Director
  16,000,000
  550,000
  15,450,000
  James Gajewski (5)
  Consultant
  46,667
  46,667
  --
  Luisa Ingargiola (6)
  CFO
  2,400,000
  2,400,000
  --
  Meng Li (7)
  COO and Director
  5,600,000
  450,000
  5,150,000
  Michael Hsu (8)
  Consultant
  26,667
  26,667
  --
  Steven A. Sanders (9)
  Director
  150,000
  150,000
  --
  Steven Sukel (10)
  Former Director
  260,000
  60,000
  200,000
  Tevi Troy (11)
  Director
  150,000
  150,000
  --
  Thomas N. Tauzin (12)
  Consultant
  489,733
  450,000
  39,733
  Uwe Sleytr (13)
  Consultant
  13,333
  13,333
  --
  Wenzhao Lu (14)
  Director
  30,045,161
  1,500,000
  28,545,161
  Wilbert J. Tauzin II (15)
  Director
  690,000
  690,000
  --
  William B Stilley, III (16)
  Director
  150,000
  150,000
  --
  Yancen Lu (17)
  Director
  5,350,000
  350,000
  5,000,000
  Yue (Charles) Li (18)
  Director
  110,000
  110,000
  --
  (1)
  The address for each of the Selling Stockholders is c/o
  Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728.
  (2)
  Under Rule 13d-3 of the Exchange Act, beneficial ownership
  includes any shares as to which the Selling Stockholder has sole or shared voting power or investment power and also any shares,
  which the Selling Stockholder has the right to acquire within 60 days. "Shares Beneficially Owned after Offering"
  assumes the sale of all of the common stock offered by this Reoffer Prospectus and no other purchases or sales of our common stock
  by the Selling Stockholders.
  (3)
  Includes shares that are issuable upon exercise of stock
  options issued pursuant to the Plan, some of which are not, and will not become vested within 60 days from December 2, 2020 and
  are not included in the calculation of "Shares Beneficially Owned Prior to this Offering."
  (4)
  Includes (i) a stock option to acquire 150,000 shares of
  common stock at an exercise price of $2.00 per share and (ii) a stock option to acquire 400,000 shares of common stock at an exercise
  price of $1.52 per share.
  5
  (5)
  Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.80 per share, (ii) a stock option to acquire 20,000 shares of common stock at an exercise
  price of $1.86 per share, and (iii) a stock option to acquire 6,667 shares of common stock at an exercise price of $1.76 per share.
  (6)
  Includes (i) a stock option to acquire 2,000,000 shares
  of common stock at an exercise price of $0.50 per share and (ii) a stock option to acquire 400,000 shares of common stock at an
  exercise price of $1.52 per share.
  (7)
  Includes (i) a stock option to acquire 150,000 shares of
  common stock at an exercise price of $2.00 per share and (ii) a stock option to acquire 300,000 shares of common stock at an exercise
  price of $1.52 per share.
  (8)
  Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $1.46 per share and (ii) a stock option to acquire 6,667 shares of common stock at an exercise
  price of $1.12 per share.
  (9)
  Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.80 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.
  (10)
  Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $1.49 per share and (ii) a stock option to acquire 30,000 shares of common stock at an exercise
  price of $2.50 per share.
  (11)
  Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.30 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.
  (12)
  Includes (i) a stock option to acquire 100,000 shares of
  common stock at an exercise price of $1.00 per share, (ii) a stock option to acquire 200,000 shares of common stock at an exercise
  price of $2.52 per share, (iii) a stock option to acquire 100,000 shares of common stock at an exercise price of $1.84 per share
  and (iv) a stock option to acquire 50,000 shares of common stock at an exercise price of $1.12 per share.
  (13)
  Includes a stock option to acquire 13,333 shares of common
  stock at an exercise price of $1.57 per share.
  (14)
  Includes a stock option to acquire 1,500,000 shares of
  common stock at an exercise price of $2.00 per share.
  (15)
  Includes (i) a stock option to acquire 290,000 shares of
  common stock at an exercise price of $1.00 per share, (ii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $2.50 per share, (iii) a stock option to acquire 40,000 shares of common stock at an exercise price of $2.75 per share,
  (iv) a stock option to acquire 40,000 shares of common stock at an exercise price of $1.93 per share, (v) a stock option to acquire
  160,000 shares of common stock at an exercise price of $2.52 per share, (vi) a stock option to acquire 80,000 shares of common
  stock at an exercise price of $1.84 per share, and (vii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $1.12 per share.
  (16)
  Includes (i) a stock option to acquire 20,000 shares of
  common stock at an exercise price of $2.30 per share, (ii) a stock option to acquire 50,000 shares of common stock at an exercise
  price of $2.75 per share and (iii) a stock option to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.
  (17)
  Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $1.49 per share, (ii) a stock option to acquire 40,000 shares of common stock at an exercise
  price of $2.50 per share, (iii) a stock option to acquire 50,000 shares of common stock at an exercise price of $2.75 per share,
  (iv) a stock option to acquire 150,000 shares of common stock at an exercise price of $2.00 per share, and (v) a stock option
  to acquire 80,000 shares of common stock at an exercise price of $1.52 per share.
  (18)
  Includes (i) a stock option to acquire 30,000 shares of
  common stock at an exercise price of $4.76 per share and (ii) a stock option to acquire 80,000 shares of common stock at an exercise
  price of $1.52 per share.
  6
  PLAN OF DISTRIBUTION
  The purpose of this
  reoffer prospectus is to allow the Selling Stockholders to offer for sale Shares acquired by the Selling Stockholders prior to
  the date of this reoffer prospectus and include 7,096,667 shares of common stock to be issued upon exercise of outstanding stock
  options.
  The decision to sell
  any shares is within the discretion of the holders thereof, subject generally to our policies affecting the timing and manner
  of sale of common stock by certain individuals and certain volume limitations set forth in Rule 144(e) of the Securities Act.
  There can be no assurance that any of the shares will be sold by the Selling Stockholders. These dispositions may be at fixed
  prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
  at the time of sale, or at negotiated prices.
  The Selling Stockholders
  may use any one or more of the following methods when disposing of common stock or interests therein:
  ●
  ordinary brokerage transactions and transactions in
  which the broker-dealer solicits purchasers;
  ●
  block trades in which the broker-dealer will attempt
  to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
  ●
  purchases by a broker-dealer as principal and resale
  by the broker-dealer for its account;
  ●
  an exchange distribution in accordance with the rules
  of the applicable exchange;
  ●
  privately negotiated transactions;
  ●
  settlement of short sales entered into after the effective
  date of the registration statement of which this prospectus is a part;
  ●
  in transactions through broker-dealers that agree
  with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;
  ●
  through the writing or settlement of options or other
  hedging transactions, whether through an options exchange or otherwise;
  ●
  a combination of any of the foregoing methods of sale;
  or
  ●
  any other method permitted pursuant to applicable
  law.
  If the Selling Stockholder
  effects such transactions by selling shares of our common stock to or through underwriters, broker-dealers or agents, such underwriters,
  broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholder
  or commissions from purchasers of our common stock for whom they may act as agent or to whom they may sell as principal (which
  discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary
  in the types of transactions involved).
  The Selling Stockholder
  and any broker-dealer participating in the distribution of our common stock may be deemed to be "underwriters" within
  the meaning of the Securities Act of 1933, as amended, and any commission paid, or any discounts or concessions allowed to, any
  such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act of 1933, as amended. At
  the time a particular offering of the securities is made, a prospectus supplement, if required, will be distributed which will
  set forth the aggregate amount of securities being offered and the terms of the offering, including the name or names of any broker-dealers
  or agents, any discounts, commissions and other terms constituting compensation from the Selling Stockholder and any discounts,
  commissions or concessions allowed, reallowed or paid to broker-dealers.
  The Selling Stockholder
  may choose not to sell any or may choose to sell less than all of our common stock registered pursuant to the registration statement,
  of which this reoffer prospectus forms a part.
  7
  We will pay the expenses
  of the registration of our common stock sold by the Selling Stockholders, including, without limitation, Securities and Exchange
  Commission filings fees; provided, however, that the Selling Stockholder will pay all underwriting discounts and selling commissions,
  if any. As and when we are required to update this reoffer prospectus, we may incur additional expenses.
  Once sold under the
  registration statement, of which this reoffer prospectus forms a part, our common stock will be freely tradable in the hands of
  persons other than our affiliates. We have notified the Selling Stockholders of the need to deliver a copy of this reoffer prospectus
  in connection with any sale of the shares.
  In order to comply
  with certain state securities laws, if applicable, the shares may be sold in such jurisdictions only through registered or licensed
  brokers or dealers. In certain states, the shares may not be sold unless the shares have been registered or qualified for sale
  in such state or an exemption from regulation or qualification is available and is complied with. Sales of shares must also be
  made by the Selling Stockholders in compliance with all other applicable state securities laws and regulations.
  In addition to any
  shares sold hereunder, Selling Stockholders may, at the same time, sell any shares of common stock owned by them in compliance
  with all of the requirements of Rule 144, regardless of whether such shares are covered by this reoffer prospectus.
  Sales by Affiliates and Sales of Restricted
  Securities
  Selling Stockholders
  who are considered "affiliates" of the Company, as defined in Rule 405 under the Securities Act, or who are selling
  "restricted securities", as defined in Rule 144(a)(3) under the Securities Act, may not sell an amount of shares pursuant
  to this reoffer prospectus which exceeds in any three month period the amount specified in Rule 144(e) under the Securities Act.
  LEGAL MATTERS
  Fleming PLLC, has passed upon the validity
  of the shares of our common stock offered by the Selling Stockholders under this prospectus.
  WHERE YOU CAN FIND MORE INFORMATION
  We are subject to the informational requirements
  of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current reports, proxy
  statements and other information with the Securities and Exchange Commission (the "Commission"). Such reports, proxy
  statements and other information can be read and copied at the Commission's public reference facilities at 100 F Street,
  N.E., Washington, D.C. 20549, at prescribed rates. Please call the Commission at 1-800-732-0330 for further information on the
  operation of the public reference facilities. In addition, the Commission maintains a website that contains reports, proxy and
  information statements and other information regarding registrants that file electronically with the Commission. The address of
  the Commission's website is www.sec.gov.
  We make available free of charge on or
  through our website at www.workhorse.com, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
  Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act
  of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it
  to the Commission. Information on our website is not incorporated by reference in this prospectus and is not a part of this prospectus.
  We will provide without charge to each
  person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information that
  has been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings,
  unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to
  us at: 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728, Attention: Chief Financial Officer.
  8
  INCORPORATION OF CERTAIN INFORMATION BY
  REFERENCE
  The Commission allows us to "incorporate
  by reference" the information we have filed with it, which means that we can disclose important information to you by referring
  you to those documents. The information we incorporate by reference is an important part of this reoffer prospectus, and later
  information that we file with the Commission will automatically update and supersede this information. We incorporate by reference
  the documents listed below and any future documents we file with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d)
  of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination of
  the offering (excluding, in either case, information that has been "furnished" but not "filed" for purposes
  of the Exchange Act).
  ●
  Annual
                                           Report on
  Form 10-K
  for the fiscal year ended December 31, 2019, filed with the Securities
                                           and Exchange Commission on April 6, 2020;
  ●
  Quarterly
                                           Reports on Form 10-Q for the fiscal quarters ended
  March 31, 2020
  ,
  June 30, 2020
  , and
  September 30, 2020
  , filed with the Securities and Exchange Commission on May 14, 2020,
                                           August 7, 2020, and November 9, 2020, respectively;
  ●
  Current
                                           Reports on Form 8-K, filed with the Securities and Exchange Commission on
  February 7, 2020
  ,
  February 24, 2020
  ,
  April 3, 2020
  ,
  August 6, 2020
  ,
  August 19, 2020
  , and
  October 22, 2020
  , respectively;
  ●
  The
                                           description of our common stock contained in the Registration Statement on
  Form 8-A
  filed
                                           on November 2, 2018 pursuant to Section 12(b) of the Exchange Act, including any amendment
                                           or report updating such description.
  9
  Reoffer Prospectus
  7,096,667 Shares
  AVALON GLOBOCARE CORP.
  Common Stock par value $0.0001
  December 8, 2020
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS
  Item 1.   Plan Information.
  The documents containing
  the information specified in Item 1 will be sent or given to participants in the Avalon GloboCare Corp. 2020 Incentive Stock Plan
  as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). Such documents are
  not required to be and are not filed with the Securities and Exchange Commission (the "Commission") either as part
  of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents
  incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute
  a prospectus that meets the requirements of Section 10(a) of the Securities Act.
  Item 2.   Registrant Information and Employee
  Plan Annual Information.
  Upon written or oral
  request, any of the documents incorporated by reference in Item 3 of Part II of this Registration Statement (which documents are
  incorporated by reference in this Section 10(a) Prospectus), other documents required to be delivered to eligible employees, non-employee
  directors and consultants, pursuant to Rule 428(b) are available without charge by contacting:
  Luisa Ingargiola, Chief Financial Officer
  Avalon GloboCare Corp.
  4400 Route 9 South, Suite 3100
  Freehold, New Jersey 07728
  732-780-4400
  I-
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  Item 3.   Incorporation of Documents by Reference.
  The following documents which have been
  filed by Avalon GloboCare Corp., a Delaware corporation (the "Registrant"), with the Commission are incorporated into
  this Registration Statement by reference:
  ●
  Annual
  Report on
  Form 10-K
  for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission on April 6,
  2020;
  ●
  Quarterly
  Reports on Form 10-Q for the fiscal quarters ended
  March 31, 2020
  ,
  June 30, 2020
  , and
  September 30, 2020
  , filed with the Securities
  and Exchange Commission on May 14, 2020, August 7, 2020, and November 9, 2020, respectively;
  ●
  Current
  Reports on Form 8-K, filed with the Securities and Exchange Commission on
  February 7, 2020
  ,
  February 24, 2020
  ,
  April 3, 2020
  ,
  August 6, 2020
  ,
  August 19, 2020
  , and
  October 22, 2020
  , respectively;
  ●
  The
  description of our common stock contained in the Registration Statement on
  Form 8-A
  filed on November 2, 2018 pursuant to Section
  12(b) of the Exchange Act, including any amendment or report updating such description.
  All documents subsequently
  filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to
  the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities
  then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this
  Registration Statement from the date of filing of such documents.
  Any statement contained
  herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed
  document that also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.
  Item 4.   Description of Securities.
  Not applicable.
  Item 5.   Interests of Named Experts and Counsel.
  Not Applicable.
  Item 6.   Indemnification of Directors and Officers.
  Section 102(b)(7)
  of the Delaware General Corporation Law (the "DGCL") allows a corporation to provide in its certificate of incorporation
  that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for
  breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged
  in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in
  violation of Delaware corporate law or obtained an improper personal benefit. The Registrant's amended and restated certificate
  of incorporation provides for this limitation of liability.
  II-
  1
  Section 145
  of the DGCL, provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to
  be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
  investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was
  an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director,
  officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys'
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such
  action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or
  not opposed to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable
  cause to believe that his or her conduct was unlawful. A Delaware corporation may indemnify any persons who were or are a party
  to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person
  is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including
  attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action
  or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the
  corporation's best interests, provided further that no indemnification is permitted without judicial approval if the officer,
  director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits
  or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including
  attorneys' fees) which such officer or director has actually and reasonably incurred.
  Section 145
  further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer,
  employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or
  agent of another corporation or enterprise, against any liability asserted against such person and incurred by such person in
  any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power
  to indemnify such person under Section 145. The Registrant's amended and restated bylaws provide that we must indemnify
  and advance expenses to its directors and officers to the full extent authorized by the DGCL.
  Further, the
  Registrant has or will enter into indemnification agreements with each of its directors and executive officers that may be broader
  than the specific indemnification provisions contained in its amended and restated bylaws or the DGCL. Such agreements may require
  the Registrant, among other things, to advance expenses and otherwise indemnify its executive officers and directors against certain
  liabilities that may arise by reason of their status or service as executive officers or directors, to the fullest extent permitted
  by law. The Registrant intends to enter into indemnification agreements with any new directors and executive officers in the future.
  The indemnification
  rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under
  any statute, any provision of the Registrant's amended and restated certificate of incorporation, the Registrant's
  amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing,
  the Registrant shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted
  by such director or officer, unless such proceeding (or part thereof) has been authorized by the board of directors pursuant to
  the applicable procedure outlined in the amended and restated bylaws.
  Section 174
  of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends
  or an unlawful stock purchase or redemption, may be held jointly and severally liable for such actions. A director who was either
  absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such
  actions to be entered in the books containing the minutes of the meetings of the board of directors at the time such action occurred
  or immediately after such absent director receives notice of the unlawful acts.
  The Registrant
  expects to maintain standard policies of insurance that provide coverage (1) to its directors and officers against loss rising
  from claims made by reason of breach of duty or other wrongful act and (2) to the Registrant with respect to indemnification
  payments that it may make to such directors and officers.
  II-
  2
  Item 7.   Exemption from Registration Claimed.
  Not
  applicable.
  Item 8.   Exhibits.
  Exhibit
      Number
  Description
  4.1
  Avalon GloboCare Corp. 2020 Incentive Stock Plan
  5.1
  Opinion of Fleming PLLC
  23.1
  Consent of Marcum LLP
  23.2
  Consent of RBSM LLP
  23.3
  Consent of Fleming PLLC (see Exhibit 5.1)
  24.1
  Power of Attorney (included in signature page)
  Item 9.
  Undertakings.
  (a)
  The
  undersigned Registrant hereby undertakes:
  (1)
  To
  file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
  i
  To
      include any prospectus required by section 10(a)(3) of the Securities Act;
  ii
  To
      reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
      recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
      set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
      offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from
      the low or high and of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
      pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change
      in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective
      registration statement; and
  II-
  3
  iii
  To
      include any material information with respect to the plan of distribution not previously disclosed in the registration statement
      or any material change to such information in the registration statement;
  provided, however, that paragraphs (1)(a)(i)
  and (1)(a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange
  Act that are incorporated by reference in this registration statement.
  (2)
  That,
      for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
      to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
      time shall be deemed to be the initial bona fide offering thereof.
  (3)
  To
      remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
      at the termination of the offering.
  (b)
  The
  undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
  of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by
  reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered
  therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
  of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the
  Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In
  the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
  or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding)
  is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant
  will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
  by the final adjudication of such issue.
  II-
  4
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto
  duly authorized, in the City of Freehold, State of New Jersey on this 8th day of December 2020.
  AVALON
      GLOBOCARE CORP.
  By:
  /s/
      David K. Jin
  David
      K. Jin
  Chief
      Executive Officer and President
  (Principal
      Executive Officer)
  By:
  /s/
      Luisa Ingargiola
  Luisa
      Ingargiola
  Chief
      Financial Officer
  (Principal
      Financial and Accounting Officer)
  Each person whose
  signature appears below constitutes and appoints David K. Jin and Luisa Ingargiola, his true and lawful attorney-in-fact and agent,
  with full power of substitution and resubstitution, severally, for him and in his name, place and stead, in any and all capacities,
  in connection with the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933, including
  to sign any and all amendments (including post-effective amendments or supplements) to this Registration Statement, and to file
  the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and
  any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, each acting
  alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
  the premises, as fully, to all intents and purposes, as he might or could do in person, hereby ratifying and confirming all that
  said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
  dates indicated.
  SIGNATURE
  TITLE
  DATE
  /s/
      David K. Jin
  Chief
      Executive Officer, President and Director
  December
      8, 2020
  David
      K. Jin
  (Principal
      Executive Officer)
  /s/
      Luisa Ingargolia
  Chief
      Financial Officer
  December
      8, 2020
  Steve
      Schrader
  (
  Principal
      Financial and Accounting Officer
  )
  /s/
      Wenzhao Lu
  Chairman
      of the Board of Directors
  December
      8, 2020
  Wenzhao
      Lu
  /s/
      Meng Li
  Chief
      Operating Officer
  December
      8, 2020
  Meng
      Li
  /s/
      Steven A. Sanders
  Director
  December
      8, 2020
  Steven
      A. Sanders
  /s/
      Yancen Lu
  Director
  December
      8, 2020
  Yancen
      Lu
  /s/
      Wilbert J. Tauzin II
  Director
  December
      8, 2020
  Wilbert
      J. Tauzin II
  /s/
      William B. Stilley III
  Director
  December
      8, 2020
  William
      B. Stilley III
  /s/
      Tevi Troy
  Director
  December
      8, 2020
  Tevi
      Troy
  /s/
      Yue "Charles" Li
  Director
  December
      8, 2020
  Yue
      "Charles" Li
  II-
  5
  Exhibit Index
  Exhibit
      Number
  Description
  4.1
  Avalon GloboCare Corp. 2020 Incentive Stock Plan
  5.1
  Opinion of Fleming PLLC
  23.1
  Consent of Marcum LLP
  23.2
  Consent of RBSM LLP
  23.3
  Consent of Fleming PLLC (see Exhibit 5.1)
  24.1
  Power of Attorney (included in signature page)
  II-6